Factor VIII inhibitors in previously treated Haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate

Thrombosis and Haemostasis

Volumn 77, Issue 1, 1997, Pages 80-86

  Peerlinck, K ^a   Arnout, J ^a   Di Giambattista, M ^b   Gilles, J G ^a   Laub, R ^b   Jacquemin, M ^a   Saint Remy, J M R ^a   Vermylen, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Rode Kruis Vlaanderen   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BISINACT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; DETERGENT; SOLVENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG SYNTHESIS; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; PASTEURIZATION; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031048881     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655911     Document Type: Article

References (24)

1. Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
2. McMillan CW, Shapiro SS, Whitehurts D, Hoyer LW, Rao V, Lazerson J, the Haemophilia Study Group. The natural history of factor VIII:C inhibitors in patients with haemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
3. Hoyer LW. Annotation. Why do so many haemophilia A patients develop an inhibitor? Br J Haematol 1995; 90: 498-501.
4. Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
5. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW. the Dutch Haemophilia Study Group. A sudden increase in Factor VIII inhibitor development in multitransfused haemophilia A patients in The Netherlands. Blood 1993; 81: 2180-6.
6. Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos A-M, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, Derlon A, Berthier A-M, Gaillard S, Bertrand M-A. Incidence of factor VIII inhibitor development in severe haemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-8.
7. Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in haemophiliacs in Europe. Vox Sang 1994; 67: 8-11.
8. Ruymann FB, Krill CE, Halpin TJ, Churchill WH, Ewenstein B, DeMaria A, MancoJohnson MJ, Hoffman RE. Hepatitis A among persons with haemophilia who received clotting factor concentrate. MMWR 1996; 45: 29-32.
9. Robinson S, Schwinn H, Josic D, Nur I, Stadler M, Bal F, Gehringer W, Schütz R. Development and biochemical characterization of a double-virus-inactivated factor VIII preparation. Blood Coagulat Fibrinol 1995; 6: 40-7.
10. Effenberger W, Oldenburg J, Budde U, Paffenholz M, Hanfland P, Brackman H-H. Entwicklung von Faktor VIII-Hemmkörpern bei vorher behandelten (PTP) Hämophilie A-Patienten unter der Anwendung eines doppelt virusinaktivierten plasmatischen Faktor VIII-Konzentrates (Octavi SD plus). Hamburger Hämophiliesymposium. Hamburg, Germany, 1995 (in press).
11. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869.
12. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test for haemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
13. Gilles JG, Arnout J, Peerlinck K, Vermylen J, Saint-Remy JM. Antifactor VIII antibodies of haemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
14. K Peerlinck, FR Rosendaal, J Vermylen. Incidence of inhibitor development in a group of young haemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-5.
15. Biggs R, Austen DEG, Denson KWE, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol 1972; 23: 125-55.
16. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-9.
17. Kasper CK. Laboratory diagnosis of factor VIII inhibitors. In: Acquired haemophilia. Kessler C, ed. Excerpta Medica Inc, 1995; p 9.
18. Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck F, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-tern follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 1624.
19. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne J-M, Giannelli F, Antonarakis SE, Cooper DN. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Research 1994; 22: 3511-45.
20. Antonorakis SE, Rossiter JP, Young M, Horst J, De Moerloose P, Sommer SS, Ketterling RP, Kazazian Jr HH, Négrier C, Vinciguerra C, Gitschier J, Goossens M, Girodon E, Ghanem N, Plassa F, Lavergne JM, Vidaud M, Costa JM, Laurian Y, Lin S-W, Lin S-R, Shen M-C, Lillicrap D, Taylor SAM, Windsor S, Valleix SV, Nafa K, Sultan Y, Delpech M, Vnencak-Jones CL, Philips III JA, Ljung RCR, Koumbarelis E, Gialeraki A, Mandalaki T, Jenkins PV, Collins PW, Pasi KJ, Goodeve A, Peake I, Preston FE, Schwartz M, Scheibel E, Ingerslev J, Cooper DN, Millar DS, Kakkar W, Giannelli F, Naylor JA, Tizzano E, Baiget M, Domenech M, Altisent C, Tussel J, Beneyto M, Lorenzo JJ, Gaucher C, Mazurier C, Peerlinck K, Matthys G, Cassiman JJ, Vermylen J, Mon PG, Acquila M, Caprino D, Inaba H. Factor VIII Gene Inversions in Severe Haemophilia A: Results of an International Consortium Study. Blood 1995; 86: 2206-12.
21. Aly AM, Aledort LM, Lee TD, Hoyer LM. Histocompatibility antigen pattern in haemophiliac patients with factor VIII antibodies. Br J Haematology 1990; 76: 238-41.
22. Scandella D, Mattingly G, de Graaf S, Fuller CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-26.
23. Gilles JG, Arnout J, Peerlinck K, Vermylen J, Saint-Remy J-M. A sudden outbreak of inhibitors during treatment with a particular pasteurized factor VIII concentrate (FVIII-CPS-P): characterization of specific antibodies. Thromb Haemost 1993; 69: 557 (abstract).
24. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briët E, Vandenberg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurized Dutch concentrate compared to classic inhibitors in haemophilia A. Thromb Haemost 1994; 71: 703-6.